Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clinical Genetics Laboratory, |
RCV001733852 | SCV001984995 | pathogenic | Ehlers-Danlos syndrome due to tenascin-X deficiency | 2020-04-01 | criteria provided, single submitter | clinical testing | PVS1, PM2, PP3 |
Ambry Genetics | RCV002370270 | SCV002662259 | uncertain significance | Cardiovascular phenotype | 2020-01-14 | criteria provided, single submitter | clinical testing | The c.7168+1G>T intronic variant results from a G to T substitution one nucleotide after coding exon 19 of the TNXB gene. This nucleotide position is highly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to abolish the native splice donor site; however, direct evidence is unavailable. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay; however, one of the predicted consequences of this variant is skipping of coding exon 19, leading to an in-frame deletion with unknown functional impact. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |